Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...
Multiple sessions at ESMO Congress 2024 covered antibody-drug conjugates (ADCs), which are an emerging therapy that holds great promise in cancer but comes with challenges. Antibody-drug conjugates ...
Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...
ADCs have transformed metastatic breast cancer care. How do you see their role evolving in earlier-stage TNBC and HR+ breast cancer? ADCs have been remarkably effective therapies and are moving ...
The clinical results from several trials suggest that patients get a high response rate from enfortumab vedotin (the antibody-drug conjugate) that is made durable from pembrolizumab (the checkpoint ...
The role of multiplexed ADCs in process control. Technical advantages of modern multiplexed ADCs. How to choose the right multiplexed ADC. Deployment tips for process-control applications. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results